Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA

Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
Conditions: Esophageal Cancer; GastroEsophageal Cancer; Gastroesophageal-junction Cancer; HER2-positive Gastric Cancer; Stomach Cancer

Interventions: Drug: Zanidatamab

Sponsors: Jazz Pharmaceuticals

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 25, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments